CLAIMS:

1. An aqueous pharmaceutical composition comprising:
   (a) adalimumab;
   (b) an acetate buffering agent (or acetate buffer system);
   (c) a sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and
   (d) polysorbate 80; and

   wherein the composition:
   - has a pH between 5.0 and 5.5;
   - is either free of arginine or comprises arginine in a concentration of at most 0.1 mM;
   - is either free of phosphate buffering agents or comprises a phosphate buffer system in a concentration of at most 0.1 mM;
   - is either free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.1 mM; and
   - is either free of surfactants, with the exception of polysorbate 80, or comprises one or more of surfactants excluding polysorbate 80 in a collective concentration of at most 0.001 mM.

2. The aqueous pharmaceutical composition as claimed in claim 1, wherein the sugar stabiliser is sucrose.

3. The aqueous pharmaceutical composition as claimed in claim 1, wherein the sugar stabiliser is trehalose.

4. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the sugar stabiliser at a concentration of 100 to 300 mM.

5. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the acetate buffering agent (or acetate buffer system) at a concentration of 5 to 50 mM.

6. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the adalimumab at a concentration of 25 to 75 mg/ml.

7. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition is free of amino acids.

8. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition is (substantially or entirely) free of polysorbate 20.

9. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the protein unfolding temperature of adalimumab in the liquid pharmaceutical composition is greater than or equal to 70°C.

10. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises:

(a) adalimumab;

(b) an acetate buffering agent (or acetate buffer system);

(c) 100 to 300 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and

(d) 0.05 to 1.5 mg/ml polysorbate 80; and

wherein the composition:

- has a pH between 5.0 and 5.5;
- is either free of arginine or comprises arginine in a concentration of at most 0.1 mM;
- is either free of phosphate buffering agents or comprises a phosphate buffer system in a concentration of at most 0.1 mM;
- is either free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.1 mM; and
- is either free of surfactants, with the exception of polysorbate 80, or comprises one or more of surfactants (excluding polysorbate 80) in a collective concentration of at most 0.001 mM.

11. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises:

(a) 5 to 75 mg/ml adalimumab;

(b) 5 to 50 mM acetate buffering agent (or acetate buffer system);

(c) 100 to 300 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and

(d) 0.9 to 1.1 mg/ml polysorbate 80; and

wherein the composition:

- has a pH between 5.1 and 5.3;
- is either free of arginine or comprises arginine in a concentration of at most 0.1 mM;
- is either free of phosphate buffering agents or comprises a phosphate buffer system in a concentration of at most 0.1 mM;
- is either free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.1 mM; and
- is either free of surfactants, with the exception of polysorbate 80, or comprises one or more of surfactants (excluding polysorbate 80) in a collective concentration of at most 0.001 mM.

12. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises:

(a) 45 to 55 mg/ml adalimumab;

(b) 5 to 50 mM acetate buffering agent (or acetate buffer system);

(c) 150 to 300 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and

(d) 0.9 to 1.1 mg/ml polysorbate 80; and

wherein the composition:

- has a pH between 5.1 and 5.3;
- is free of arginine;
- is free of phosphate buffering agents;
- is free of amino acids; and
- is free of surfactants, with the exception of polysorbate 80.

13. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises:

(a) 45 to 55 mg/ml adalimumab;

(b) 5 to 50 mM acetate buffer system comprising sodium acetate;

(c) 150 to 300 mM sucrose; and

(d) 0.9 to 1.1 mg/ml polysorbate 80; and

wherein the composition:

- has a pH between 5.1 and 5.3;
- is free of arginine;
- is free of phosphate buffering agents;
- is free of amino acids; and
- is free of surfactants, with the exception of polysorbate 80.

14. A drug delivery device comprising a liquid pharmaceutical composition as claimed in any preceding claim.

15. A liquid pharmaceutical composition as claimed in any of claims 1 to 13 for use in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and/or juvenile idiopathic arthritis.